|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910464771903321 |
|
|
Titolo |
Evidence-based management of lipid disorders / / Maud N. Vissers, John J.P. Kastelein, Erik S. Stroes, [editors] |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (322 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
VissersMaud N |
KasteleinJohn J. P |
StroesErik S |
|
|
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Lipids - Metabolism - Disorders - Treatment |
Evidence-based medicine |
Electronic books. |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
""COVER FRONT""; ""Contents""; ""Foreword""; ""Contributors""; ""Acknowledgements""; ""Using evidence-based medicine""; ""Chapter 1 How much evidence is enough?""; ""Chapter 2 A brief review of lipoprotein metabolism""; ""Chapter 3 Epidemiological aspects of lipid and lipoprotein levels in relation to cardiovascular diseases""; ""Chapter 4 Are LDL cholesterol-lowering functional food ingredients successful in the long term?""; ""Chapter 5 Evidence-based treatment of primary hypo- and hypercholesterolemic disorders""; ""Chapter 6 Does raising HDL protect against atherosclerosis?"" |
""Chapter 7 How do we diagnose hypertriglyceridemia in clinical practice and what are the consequences for treatment?""""Chapter 8 The optimal treatment of patients with familial combined hyperlipidemia""; ""Chapter 9 How to manage lipid and lipoprotein disorders in children""; ""Chapter 10 Contribution of the atherogenic dyslipidemic phenotype to the increased cardiovascular disease risk of the metabolic syndrome and diabetes mellitus""; ""Chapter 11 What are the consequences of renal insufficiency or the nephrotic syndrome for lipid levels?"" |
""Chapter 12 The link between chronic inflammatory diseases and |
|
|
|
|